222 related articles for article (PubMed ID: 25090648)
1. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
Shirato H; Someya Y; Ochiai M; Horiuchi Y; Takahashi M; Takeda N; Wakabayashi K; Ouchi Y; Ota Y; Tano Y; Abe S; Yamazaki S; Wakita T;
Vaccine; 2014 Sep; 32(40):5163-9. PubMed ID: 25090648
[TBL] [Abstract][Full Text] [Related]
2. Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine.
Sun M; Ma Y; Xu Y; Yang H; Shi L; Che Y; Liao G; Jiang S; Zhang S; Li Q
Vaccine; 2014 Feb; 32(9):1100-6. PubMed ID: 24412578
[TBL] [Abstract][Full Text] [Related]
3. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
4. [Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
Ma Y; Qin M; Hu HQ; Ji G; Feng L; Gao N; Gu J; Xie BF; He JH; Sun MB
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):197-200. PubMed ID: 21977591
[TBL] [Abstract][Full Text] [Related]
5. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.
Murakami K; Fujii Y; Someya Y
Vaccine; 2020 Apr; 38(17):3295-3299. PubMed ID: 32197923
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
[TBL] [Abstract][Full Text] [Related]
8. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the use of various rat strains for immunogenic potency tests of Sabin-derived inactivated polio vaccines.
Someya Y; Ami Y; Takai-Todaka R; Fujimoto A; Haga K; Murakami K; Fujii Y; Shirato H; Oka T; Shimoike T; Katayama K; Wakita T
Biologicals; 2018 Mar; 52():12-17. PubMed ID: 29475730
[TBL] [Abstract][Full Text] [Related]
10. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan.
Satoh H; Tanaka-Taya K; Shimizu H; Goto A; Tanaka S; Nakano T; Hotta C; Okazaki T; Itamochi M; Ito M; Okamoto-Nakagawa R; Yamashita Y; Arai S; Okuno H; Morino S; Oishi K
Vaccine; 2019 Mar; 37(14):1964-1971. PubMed ID: 30827736
[TBL] [Abstract][Full Text] [Related]
11. The progress of postapproval clinical studies on Sabin IPV.
Shi L; Sun M
Hum Vaccin Immunother; 2022 Dec; 18(1):1-4. PubMed ID: 34213408
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
[TBL] [Abstract][Full Text] [Related]
14. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
Shimizu H
Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
[TBL] [Abstract][Full Text] [Related]
15. sIPV process development for costs reduction.
Thomassen YE; Bakker WA
Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
[TBL] [Abstract][Full Text] [Related]
16. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.
Shin WJ; Hara D; Gbormittah F; Chang H; Chang BS; Jung JU
mBio; 2018 Nov; 9(6):. PubMed ID: 30482835
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine.
Sato Y; Shiosaki K; Goto Y; Sonoda K; Kino Y
Biologicals; 2013 May; 41(3):184-9. PubMed ID: 23375165
[TBL] [Abstract][Full Text] [Related]
18. Alternative delivery of a thermostable inactivated polio vaccine.
Kraan H; Ploemen I; van de Wijdeven G; Que I; Löwik C; Kersten G; Amorij JP
Vaccine; 2015 Apr; 33(17):2030-7. PubMed ID: 25772676
[TBL] [Abstract][Full Text] [Related]
19. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].
Gendon IuZ; Markushin SG; Akopova II; Krivtsov GG; Akhmatova NK; Koptiaeva IB; Vasil'ev IuM
Vopr Virusol; 2011; 56(6):28-32. PubMed ID: 22359946
[TBL] [Abstract][Full Text] [Related]
20. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.
Thomassen YE; van 't Oever AG; van Oijen MG; Wijffels RH; van der Pol LA; Bakker WA
PLoS One; 2013; 8(12):e83374. PubMed ID: 24349497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
